Fio Corporation - CEO, Dr. Michael Greenberg
CEO, Dr. Michael Greenberg
Source: YouTube
  • Scryb Inc. (SCYB) and Fio Corporation announce the launch of FlyClear™ with LifeLabs® for COVID-19 testing for those flying internationally
  • FlyClear™ Pre-Departure Testing will be available Lester B. Pearson International Airport and will also soon be for the Vancouver International Airport
  • FlyClear™ provides passengers with fast results, allowing passengers to travel more effectively
  • The device used is an intuitive portable device that maximizes rapid diagnostic test processing accuracy with on-screen procedure guidance
  • Scryb Inc. (SCYB) is up 2.70 per cent and is trading at $0.19 per share as of 2:56 p.m. EST

Scryb (SCYB) and Fio Corporation have launched FlyClear™ with LifeLabs® providing rapid COVID-19 pre-departure testing for those flying internationally.

It is being launched through Scryb and Fio’s joint venture, Fionet Rapid Response Group (FRR).

FlyClear™ Pre-Departure Testing will be available at Lester B. Pearson International Airport.

The FlyClear™ location at the Vancouver International Airport is expected to be open for testing soon.

Dr. Michael Greenberg, CEO of Fio, stated,

“Supporting LifeLabs in this capacity offers passengers departing from Pearson to conveniently access pre-departure COVID-19 PCR/NAAT/antigen testing.”

LifeLabs is using FRR’s Fionet Deki device to conduct COVID-19 rapid antigen testing.

The device maximizes rapid diagnostic test accuracy by providing frontline workers with high-quality testing. The Fionet Deki is connected to LifeLabs’ Laboratory Information System (LIS).

Fionet Rapid Response Group reports the successful deployment of its Deki device for rapid COVID-19 testing at various events, including the FIFA World Cup™ Qualifying match, the 2022™ Tennis Canada’s National Bank Open Presented by Rogers, and Toronto’s International Film Festival.

Scryb Inc. (SCYB) is up 2.70 per cent and is trading at $0.19 per share as of 2:56 p.m. EST.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.